App-Quantinova.ai

Is HLA-B27 a predictor of treatment response to biologics in psoriatic arthritis?

Trixy David - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

The association between gravidity, parity and the risk of rheumatoid arthritis: a systematic review and meta-analysis of observational studies

Winnie M Y Chen - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

The long-term progression of disease activity, functional disability and quality of life using data from two early RA cohorts

Lewis Carpenter - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

If I tweet more about my paper, will I improve my citation index?

Winnie M Y Chen - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Predictors of resilience in severe rheumatoid arthritis: an analysis of data from the Norfolk Arthritis Register

Jordan Tsigarides - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Characteristics of patients with prevalent giant cell arteritis in UK primary care

Elizabeth L Twomlow - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Prednisolone

Results of a patient survey on feasibility and face validity of outcome measures for intended use in future studies enrolling participants with polymyalgia rheumatica

Max Yates - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

Ethnicity in giant cell arteritis

Jonathan Pinnell - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

Converting patients with chronic myositis from maintenance intravenous immunoglobulin therapy to rituximab in England: a potential saving of £1.7 million per year

Alexander Oldroyd - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Myositis

Rituximab

Discrepancy between solid-phase immunoassays and immunoprecipitation in detecting anti-TIF1 gamma in patients with myositis

Sarah Tansley - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Myositis

N/A

Quantitative strength profiling in inclusion body Myositis: faster deterioration in males and positive associations with functional assessment tools

James B Lilleker - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Inclusion body myositis

N/A

Investigating the sensitivity and specificity of the myositis profile-4 EUROLINE assay

Clara Ventn-Rodrguez - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Scleroderma

N/A

Patient organisation-led initiatives can play an important role in raising awareness about Raynaud’s phenomenon and encourage earlier healthcare utilisation for high risk groups

Michael Hughes - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Raynaud syndrome

N/A

A cross-sectional study characterising ultrasound findings in the finger flexor tendon complex in systemic sclerosis

Michael Hughes - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Raynaud syndrome

Orphenadrine Citrate

Disease duration and autoantibodies determine distinct skin score trajectories in diffuse cutaneous systemic sclerosis

Svetlana I Nihtyanova - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Scleroderma

N/A

Disease-specific autoantibodies associate with remarkably different risk of development of significant lung fibrosis in systemic sclerosis

Svetlana I Nihtyanova - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Mass cytometry analysis reveals dysregulated T cell complement responses in diffuse cutaneous systemic sclerosis

Giuseppina Arbore - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

A monoclonal antibody against BDCA-2 inhibits TLR-induced activation of human pDC in vitro and in vivo: a novel therapeutic target for systemic sclerosis

Clarissa Corinaldesi - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Imiquimod

Serum interferon score predicts clinical outcome at 12 months in diffuse cutaneous systemic sclerosis as measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)

Antonio Carriero - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Interferon

Feasibility study of Raster-scanning optoacoustic mesoscopy for imaging nailfold capillaries in healthy controls and patients with systemic sclerosis

Andrea K Murray - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Filters

45280 Abstracts